Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 87

Results For "CAS"

1859 News Found

Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states
News | June 22, 2023

Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states

Effective disaster response and management is a collaborative work


Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
News | June 21, 2023

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency


Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals
News | June 21, 2023

Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals

This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments


Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
News | June 19, 2023

Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines

Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic


MoS Health addresses TB Health Technologies workshop
News | June 17, 2023

MoS Health addresses TB Health Technologies workshop

Urges Innovators to produce quality products that can be deployed at scale


InnoCan submits new patent applications for advanced pain relief technology
News | June 13, 2023

InnoCan submits new patent applications for advanced pain relief technology

The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution


Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
News | June 12, 2023

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease